Captrust Financial Advisors Decreases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Captrust Financial Advisors trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,570 shares of the company’s stock after selling 3,142 shares during the quarter. Captrust Financial Advisors’ holdings in CRISPR Therapeutics were worth $1,125,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP raised its holdings in shares of CRISPR Therapeutics by 55.1% during the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock worth $51,483,000 after purchasing an additional 464,936 shares during the period. Bank of America Corp DE raised its holdings in shares of CRISPR Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 1,211,509 shares of the company’s stock worth $47,685,000 after purchasing an additional 129,746 shares during the period. Benjamin Edwards Inc. raised its holdings in shares of CRISPR Therapeutics by 37.8% during the fourth quarter. Benjamin Edwards Inc. now owns 45,062 shares of the company’s stock worth $1,774,000 after purchasing an additional 12,359 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of CRISPR Therapeutics by 9.9% during the fourth quarter. Ameriprise Financial Inc. now owns 205,173 shares of the company’s stock worth $8,072,000 after purchasing an additional 18,412 shares during the period. Finally, Alteri Wealth LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $217,000. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $35.60 on Thursday. The stock’s 50 day moving average is $37.71 and its 200 day moving average is $42.56. The firm has a market cap of $3.07 billion, a P/E ratio of -8.15 and a beta of 1.88. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics’s revenue was up 71.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.43) earnings per share. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRSP has been the topic of a number of analyst reports. Stifel Nicolaus dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a report on Wednesday, February 12th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, March 21st. Barclays decreased their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday, May 9th. Finally, Royal Bank of Canada decreased their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.